MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor - Pharmaceutical Technology

MSD's bet on targeting RAS comes amid the industry buzz around the approval of Revolution's OS-doubling pancreatic cancer drug, Rasonque. This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer treatment, Rasonque. MSD inks this deal as the pharma industry takes increasing interest in anti-tumour potential of drugging the RAS pathway. Credit: Tada Images / Shutterstock.com. MSD (Merck & Co) has once again turned to China to fortify its pipeline – this time inking a licensing deal with Shanghai-based biotech, SciBrunch Therapeutics, centred around a KRAS inhibitor, SPR2015, as buzz around targeting the…

Source: Pharmaceutical Technology